pros and cons of glp 1 agonists GLP-1 Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) receptor (semaglutide [Wegovy, Ozempic, Rybelsus]) dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind GLP-1 receptor agonists and next-generation

Important discussion points include: Medical history : Disclose any history of thyroid problems (especially MTC), MEN2, pancreatitis, gallbladder disease, kidney disease, gout, liver disease, or alcohol use Treatment goals : Clarify whether niacin therapy is necessary given current lipid management guidelines, which generally favor statins, ezetimibe, PCSK9 inhibitors, or other agents before niacin for cardiovascular risk reduction Glucose monitoring plan : Establish a clear schedule for blood glucose checks and hemoglobin A1c testing (typically every 3 months) to assess the combination's net effect on glycemic control Liver monitoring plan : Discuss the schedule for liver function tests if taking pharmacologic doses of niacin (baseline, 6-8 weeks during titration, and periodically thereafter) Pregnancy planning : If applicable, discuss contraception needs, as tirzepatide may reduce oral contraceptive effectiveness during initiation and dose escalation Symptom management : Review strategies for managing potential side effects from both medications, including the timing of niacin doses to minimize flushing and approaches to mitigate tirzepatide's gastrointestinal effects Patients should specifically ask about the expected timeline for therapeutic effects, warning signs that require immediate medical attention (severe abdominal pain, yellowing of skin/eyes, unusual fatigue, neck swelling), and whether any dose adjustments to existing diabetes medications may be necessary

Brain V Booster Enhances brain repair, improves focus, and reduces mental fatigue

Formulas specifically designed for sensitive or rosacea-prone skin offer adequate protection without triggering new flares

RSH + GSSG RSSG + GSH Glutathionylation is common in the cytosol and mitochondria

Each vial contains 2.5 g (100 mg/mL, 25 mL) of glutathione powder for solution, designed for intravenous (IV) infusion

When integrated thoughtfully, peptides may supportbut not replacethe foundation of injury recovery